Jubilant Pharma inks vaccine manufacturing agreement with US for $149.6 M

31 May 2022 | News

Jubilant HollisterStier has a long history of supporting the US Department of Health and Human Services (HHS) and Department of Defense (DOD) biodefense and medical countermeasure programmes

Image Credit: Shutterstock

Image Credit: Shutterstock

Jubilant Pharmova has announced that Jubilant Pharma, a wholly-owned subsidiary of the company, through one of its wholly-owned subsidiaries, Jubilant HollisterStier (JHS)- a leading US-based pharmaceutical contract manufacturer, has entered into a cooperative agreement for $149.6 million with the Army Contracting Command, in coordination with the Joint Programme Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of the Biomedical Advanced Research and Development Authority (BARDA), within the US Department of Health and Human Services.


The effort was funded under the American Rescue Plan, this agreement will enable the company to double its injectable filling production capacity at a total cost of $193 million, at its Spokane, Washington manufacturing facility. This will be completed by 2025.


This agreement is in addition to the $92 million filling line expansion announced in November 2021, which will be commercially available by the end of 2024.




× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account